The National Institutes of Health (NIH) has awarded $7.8 million for the launch of a rare disease network, called MGNet, to drive research in myasthenia gravis and which will be led by experts from George Washington University, Yale University, and Duke University. The network…
Treatment with Soliris (eculizumab) provides comparable and sustained improvements in daily living and muscle strength in Japanese and Caucasian patients with treatment-resistant generalized myasthenia gravis (gMG), according to one-year data of REGAIN’s extension study. Efficacy and safety were maintained up to 52 weeks in both patient groups and were consistent…
People with myastenia gravis (MG) whose disease is refractory, or resistant, to conventional therapies, are more likely to have disease flare-ups, visit an emergency room, be hospitalized, or be admitted to an intensive care unit — using more healthcare resources — than patients with nonresistant MG, a U.S. study…
Examining differences in the activity of certain genes may help explain why some patients with myasthenia gravis (MG) develop a difficult-to-treat form of the disease in the eyes. Researchers used laboratory models derived from patient cells to re-create MG muscle cells, and study their gene activity. The findings…
Placebo-treated myasthenia gravis (MG) patients experience as many adverse events as those receiving an active treatment during clinical trials, but this leads to few participant dropouts — and should not represent a problem for patient compliance to placebo during trials, a grouped analysis of studies shows. The study, “…
Researchers have identified five candidate therapies for treating myasthenia gravis (MG) by using a new computational model that also predicts key biological processes involved in the disease. The study, “Building the drug-GO function network to screen significant candidate drugs…
Prograf (Tacrolimus) may be a beneficial treatment for people with myasthenia gravis (MG), helping reduce steroid use and disease scores, a joint analysis of several studies shows. The review, “Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis” was published in the…
MG-ADL, a patient-reported scale commonly used to address symptom severity in myasthenia gravis (MG), has a poor sensitivity for measuring generalized muscle weakness. Researchers suggest that more questions about it be added. The study, titled “Sensitivity of MG-ADL for generalized weakness in myasthenia gravis,” was published…
Commonly used clinical scales to measure symptom severity in myasthenia gravis (MG) patients are insufficient to precisely evaluate swallowing problems and predict the risk of silent aspiration, a study reports. Patients with difficulty swallowing and disease severity classified…
Gut microbiota is altered in people with myasthenia gravis (MG), opening the door for exploring the use of microbiota-modulating therapies, like probiotics, as potential ways of better managing the disease. Results of the pilot study, “Fecal microbiota profile in a group of myasthenia gravis patients,” were published in…
Get regular updates to your inbox.